Similarly, KRAS G12D mutations and MAPK1 (MEK) and MET amplification are published biomarkers for colorectal tumor sensitivity to both MEK and MET inhibitors [3, 4]. The gene discussed is KRAS; the disease is colorectal neoplasm.